Skip to main content
. 2013 Nov 14;3(11):e002957. doi: 10.1136/bmjopen-2013-002957

Table 5.

Hospital-driven criteria in the selection of phase II–III trial sites (phase III–IV for medical devices)

Mean Upper 95% CL Lower 95% CL
Site personnel experience and training 22.0 23.1 20.84
Previous experience with site 20.0 21.2 18.7
Facilities/equipment required by trial 19.7 20.7 18.7
Hospital approval/contracting system 17.4 18.5 16.4
Site personnel language proficiency 10.8 11.7 10.0
Hospital quality assurance process 10.1 10.9 9.2

Respondents (N=341) were asked to rate hospital-driven criteria by dividing 100 points across six criteria potentially used when selecting trial sites for phase III studies: Pharma, Biotech, CROs and CTUs answered for phase III studies. Medical device and all others answered for phase IV studies. There was evidence of a statistically significant difference in the level of importance of the six criteria (p<0.0001).

CL, confidence limit; CROs, clinical research organisations; CTUs, clinical trial units.